Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Patent
1995-06-06
1997-08-26
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
514303, 546118, A61K 4900
Patent
active
056608136
ABSTRACT:
This invention provides a method of and compositions for increasing or maintaining glomerular filtration rate while preserving renal structure in a patient comprising administering an angiotensin II type 1 vascular receptor antagonist to the patient, independent of its effects on systemic blood pressure. The invention provides that, by administering an AII type 1 receptor antagonist, blood flow to the kidney can be improved without sacrificing intraglomerular pressure and therefore glomerular filtration and that even with this enhanced glomerular pressure and filtration, renal structure is preserved. Also provided is a method of screening AII type 1 receptor antagonists for the ability to maintain or increase glomerular filtration rate while decreasing mesangial matrix accumulation comprising the steps of administering the antagonist in an animal model characterized by decreased glomerular filtration rate and increased mesangial matrix accumulation and selecting the compounds that increase glomerular filtration rate while decreasing mesangial matrix accumulation.
REFERENCES:
patent: 5049565 (1991-09-01), Chen et al.
patent: 5087702 (1992-02-01), Chen et al.
Kon et al. "Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition", Kidney Internat'l 44:545-550, Sep. 1993.
Peten et al. "High dose ACE inhibitor (ACEI) or ANGII receptor antagonist (ANGII RI) therapy does not improve glomerulosclerosis (GS) in mice transgenic for growth hormone (GH MICE)", J. Am. Soc. Nephrol. Abstract vol. 4(3), p. 780, Sep. 1993.
Kakinuma et al. "Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure", Kidney Internat'l 42(1):46-55, Jul. 1992.
Chan et al. "Renal-specific actions of angiotensin II receptor antagonism in the anesthetized dog" Am. J. Hypertens. 5:354-360, Jun. 1992.
Kivlighn et al. "Antihypertensive efficacy and effects on renal function of L-158,809: A nonpeptide orally active angiotension II antagonist" Hypertension Abstract 19(1):I-135, Jan. 1992.
Kivlighn et al. "Antihypertensive efficacy and effects on renal function in the conscious spontaneously hypertensive rat(SHR)" FASEB Journal Abstract vol. 5(5), p. A1576, Mar. 19, 1991.
Bovee et al. "Effects of the nonpeptide angiotensin II receptor antagonist DuP 753 on blood poressure and renal functions in spontaneously hypertensive PH dogs" Am. J. Hypertens. 4:327S-333S, Apr. 1991.
Takeda, et al. Kidney International, 42:1713-1719, 1992.
Fogo et al. Kidney International 42:770-774, 1992.
Awazu et al. J. Amer Soc. Nephrology, 1:1253-1258, 1991.
Kon and Badr Kidney International, 40:1-12, 1991.
Kon et al., Kidney International. 37:1487-1491, 1990.
Chang et al. FASEB 5(Part 111):6993 (Abstr) 1991.
Fogo Agnes
Ichikawa Iekuni
Kon Valentina
Raymond Richard L.
Vanderbilt University
LandOfFree
Method of screening of angiotens in II type I receptor antagonis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of screening of angiotens in II type I receptor antagonis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of screening of angiotens in II type I receptor antagonis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1986283